Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Phase 2
Completed
- Conditions
- GastrinomaPancreatic Polypeptide TumorRecurrent Islet Cell CarcinomaGlucagonomaInsulinomaRecurrent Pancreatic CancerSomatostatinomaStage IV Pancreatic CancerStage III Pancreatic Cancer
- Interventions
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Shaheen Shagufta
- Target Recruit Count
- 20
- Registration Number
- NCT01525082
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
News
No news found